Metastatic prostate cancer is associated with considerable morbidity and mortality. Standard
treatment for non-metastatic prostate cancer, to prevent metastatic progression, is androgen …

Background/Aim: Prostate cancer is one of the most common cancers in men which remains
a global public health issue. Treatment of prostate cancer is becoming increasingly intensive …

The development of targeted therapies has been a consistent goal for hormone-related
diseases treatment. As a result of increased knowledge of the role of androgens in different …

Purpose: No published head-to-head randomized trials have compared the safety and
efficacy of darolutamide vs apalutamide or enzalutamide in nonmetastatic castration …

Background As a kind of traditional Chinese medicine, HQ is widely mentioned in the
treatment of cancerous diseases in China, which has been proven to have a therapeutic …

Lately the development of 3 novel second-generation androgen receptor antagonists
(enzalutamide, apalutamide, and darolutamide) chanced the treatment landscape of …

Prostate cancer is the second most common cause of cancer-related mortality in men. In
patients undergoing a failure after radical treatment, one of the therapeutic option is …

Cocrystallization and coamorphization are similar yet independent approaches toward
modifying various pharmaceutically relevant properties of modern drug compounds, in …

Men treated with androgen deprivation therapy for rising PSA after failed local therapy will
often develop castrate resistance, and the appearance of metastases predicts a poor …

Purpose Resistance to androgen-deprivation therapies and progression to so-called
castrate-resistant prostate cancer (CRPC) remain challenges in prostate cancer (PCa) …